Abstract
Background Soluble suppression of tumorigenicity-2 (sST2) predicts mortality in heart failure patients. The predictive value of sST2 in left ventricular assist device (LVAD) patients remains unknown. Therefore, we studied the relationship between sST2 and outcome after LVAD implantation.
Methods Patients implanted between January 2015 and December 2022 were included. Survival of patients with normal and elevated pre-operative sST2 levels was compared using Kaplan-Meier analysis. The relationship between post-operative sST2, survival and right heart failure (RHF) was evaluated using a Joint Model (JM). Multivariate JM analysis adjusted for serially measured NT-proBNP was performed.
Results The median follow-up was 25 months, during which 1573 post-operative sST2 levels were measured in 199 patients, with a median of 29 ng/ml. Survival in patients with normal or elevated pre-operative sST2 levels (n=86) did not differ significantly (p=0.22). Time-dependent post-operative sST2 levels were significantly associated with mortality, with a hazard ratio (HR) of 1.20 (95% CI: 1.10-1.30, p<0.01) and a HR of 1.22 (95% CI: 1.07-1.39, p=0.01) for RHF, both per 10 unit sST2 increase. The sST2 instantaneous change was not predictive for survival or RHF (p=0.99, p=0.94 respectively). Multivariate JM analysis showed a significant relationship between sST2 with mortality adjusted for NT-proBNP with HR 1.19 (95% CI: 1.00-1.42, p=0.05), while the HR of RHF was not significant (1.22, 95% CI: 0.94-1.59, p=0.14), both per 10 unit sST2 increase.
Conclusion Time-dependent post-operative sST2 predicts all-cause mortality after LVAD implantation independently of NT-proBNP. Future research is warranted into possible target interventions and the optimal monitoring frequency.
Competing Interest Statement
L.N., E.A., F.R., M.G.M., N.J., A.M.O., H.K.F.A. have no conflict of interest. L.W.L received consultancy fees from Medtronic, Abbott Vifor, Novartis, outside the submitted work. M.I.F.J.O. received consultancy fees from Alnylam, Pfizer, Johnson & Johnson and Novartis paid to the University Medical Center Utrecht, outside the submitted work.
Clinical Trial
-
Funding Statement
The collaboration project is co-funded by the PPP Allowance made available by Health-Holland, Top Sector Life Sciences & Health, to stimulate public-private partnerships (LVAD-LVAD, LSHM19035).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the local ethics committee of the UMCU (no: 20-195) and was handled in accordance with the Declarations of Helsinki and Good Clinical Practice.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will not be made publicly available.
Non-standard Abbreviations and Acronyms
- HM3
- HeartMate 3
- HVAD
- HeartWare
- HTx
- heart transplantation
- IL-33
- interleukin-33
- INTERMACS
- Interagency Registry for Mechanically Assisted Circulatory Support
- JM
- joint model
- LME
- linear mixed effects
- LVAD
- left ventricular assist device
- sST2
- Soluble suppression of tumorigenicity-2
- UMCU
- University Medical Hospital Utrecht
